8-K: Regenerative Medical Tech CEO Addresses Investor Concerns

Regenerative Medical Technology Group Inc. CEO Dave Christensen discussed the company's path to Nasdaq, revenue growth, liabilities, and strategic initiatives during an investor video call.

Summary

• Regenerative Medical Technology Group Inc. (RMTG) held an investor video call on August 20, 2026, where CEO Dave Christensen addressed shareholder questions.
• The company is working towards an uplisting to Nasdaq, which involves meeting specific financial thresholds and aligning the balance sheet.
• Revenue growth was highlighted, with Q1 2026 revenue up 90% year-over-year and Q2 revenue quadrupling year-over-year.
• Management acknowledged significant liabilities and interest expenses, attributing them to business investments, including the acquisition of Global Stem Cell Group and expansion into Argentina.
• The strategy to address liabilities involves scaling higher-margin, recurring revenue products and services, such as the ISSCA training program and affiliate model.
• The company's partnership with Bare Knuckle Fighting Championship (BKFC) as its official regenerative medicine partner was discussed, with expectations of further public announcements.
• The development of ISSCA Ai, leveraging a large database of medical records to provide predictive health profiles for patients, was explained as a new revenue opportunity.
• Management is exploring strategies to raise capital and maintain a tight stock structure, referencing a past reduction in authorized shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, with management addressing key investor concerns and highlighting growth drivers, though significant liabilities remain a point of focus.

Positives

• Significant year-over-year revenue growth reported for Q1 2026 (90%) and Q2 2026 (quadrupled).
• Progress is being made towards meeting Nasdaq listing requirements.
• The ISSCA education and training program is a strong growth driver and recurring revenue source.
• The affiliate model creates branded extensions and provides recurring revenue.
• Expansion into Argentina with a new license to harvest and produce biologics is a significant achievement.
• Development of ISSCA Ai leverages a large database to offer predictive health profiles, creating a new revenue opportunity.
• The company is exploring strategies to raise capital while aiming to maintain a tight stock structure.

Negatives

• The company carries significant liabilities and growing interest expenses.
• Investments made to grow the business have resulted in increased debt.
• The path to Nasdaq is complex and cannot be guaranteed in terms of timing.
• Regulatory challenges for regenerative medicine persist, particularly in the U.S.

Risks

• The company's significant liabilities and interest expenses could impact financial stability.
• The timing and success of achieving Nasdaq listing requirements are uncertain.
• Regulatory hurdles in the U.S. for regenerative medicine may slow adoption and growth.
• Reliance on continued investment and scaling of higher-margin products to manage debt.

Future Outlook

The company is focused on scaling higher-margin, recurring revenue products and services to address liabilities. They anticipate continued growth from ISSCA events, the affiliate model, and potential new announcements related to the BKFC partnership. The development and implementation of ISSCA Ai are expected to provide a new revenue stream and predictive health insights. Management is also actively exploring capital raising strategies.

Management Comments

• "We have to align the business, to align the balance sheets up with those standards and those tiers, and then file the application for Nasdaq review."
• "The plan is to close that gap, and how we can do that, we just scale higher margin, our products, in the recurring parts of our business."
• "We believe going forward, we expect more public announcements to support the business."
• "The company is looking at different strategies on how to raise capital."
• "The most conservative forecasters are saying that regenerative medicine as an industry can be a 30 to 40 billion dollar industry over the next 10-20 years."
• "We are constantly measuring whats happening in our business models, but I think most of our effort really is spent on building the business, building the business, making it real."

Industry Context

StockSavvy.ai notes that the regenerative medicine industry is projected to grow significantly, with conservative estimates placing it between $30-40 billion in the next 10-20 years. The company's focus on education (ISSCA), product supply, and clinical services, along with advancements in AI for predictive health, aligns with key industry trends. The challenges faced with U.S. regulations are contrasted with progress in countries like Argentina, highlighting a global push for regenerative therapies.

Stakeholder Impact

• Shareholders: Potential for stock price volatility related to capital raise strategies and Nasdaq uplisting progress. Continued focus on building business value.
• Employees: Continued focus on business growth and expansion may lead to new opportunities.
• Customers: Access to advanced regenerative medicine training, products, and AI-driven health insights.
• Creditors: The company's strategy to address liabilities through revenue growth and margin improvement is crucial for maintaining creditor confidence.

Next Steps

• Continue working towards meeting Nasdaq listing requirements.
• Scale higher-margin products and recurring revenue streams.
• Execute on the BKFC partnership with potential for further public announcements.
• Expand ISSCA events globally, including a summit in Cancun and an event in Dubai.
• Continue building and expanding operations, including the new clean rooms in the Cancun lab.
• Develop and leverage ISSCA Ai for predictive health insights and physician relationships.
• Explore and implement capital raising strategies.

Key Dates

Recommendation

The company demonstrates strong revenue growth and strategic initiatives in a high-potential industry. However, significant liabilities and the uncertainty surrounding the Nasdaq uplisting timeline warrant a cautious 'hold' recommendation. Investors should monitor debt reduction strategies and progress towards listing requirements.

Keywords

Regenerative Medicine, Stem Cells, ISSCA, Investor Call, Nasdaq Uplisting, Revenue Growth, Capital Raise, Biologics